Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

Trump admin’s Medicaid block grants met with industry backlash

Medicaid block grants, which have been framed as an “opportunity” for states to better control their Medicaid spending and gain flexibility, have been harshly criticized by healthcare groups.

Thumbnail

Will AI be a part of Trump’s State of the Union address?

President Trump is scheduled to deliver his State of the Union address on Tuesday, Feb. 4, at a time when most Americans have been focused on impeachment, the 2020 election and the coronavirus outbreak.

Thumbnail

Trump administration announces Medicaid block grants under new branding

The Trump administration has released its Medicaid block grant program under a new name that allows states to designate funding and put a cap on Medicaid spending. The program, dubbed Healthy Adults Opportunity, is an optional intervention initiative that fundamentally changes the way part of Medicaid is funded.

Thumbnail

CVS debuts insulin program with no out-of-pocket costs

CVS Health recently launched an insulin program for employers and health plan sponsors to offer diabetes medications with zero out-of-pocket costs for members. The program could help alleviate the rising costs of insulin for people managing diabetes.

Thumbnail

CMS expands coverage to genetic sequencing for cancer patients

CMS will now cover Next Generation Sequencing through FDA-approved or cleared lab diagnostic tests for patients with inherited ovarian or breast cancer.

Thumbnail

Pharma industry lobbying hit $29M in 2019

The pharmaceutical industry upped its lobbying efforts in 2019, with a record-high of $29 million spent lobbying Congress.

Thumbnail

Civica Rx, Blue Cross Blue Shield tackle high-cost generic medications with new subsidiary

Civica Rx and the Blue Cross Blue Shield Association and 18 of its health plans have teamed up to create a new subsidiary that will target low-cost generic drugs.

Thumbnail

How US could fall behind China in AI development

The United States is still viewed as the world’s leader in researching and developing AI solutions—but could that reputation be at stake?

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup